Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 25;4(5):e00520-19.
doi: 10.1128/mSphere.00520-19.

Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development

Fikri Avci  1 , Francesco Berti  2 , Peter Dull  3 , John Hennessey  4 , Viliam Pavliak  5 , A Krishna Prasad  6 , Willie Vann  7 , Michael Wacker  8 , Olivier Marcq  9
Affiliations

Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development

Fikri Avci et al. mSphere. .

Abstract

Glycoconjugate vaccines are a critical component of the medical arsenal against infectious diseases. This established field continues, however, to experience failures in the clinic. The lack of fundamental understanding of factors controlling clinical efficacy of glycoconjugate vaccines is discussed while key parameters demanding focused and collaborative research are identified.

Keywords: T-cell immunity; capsular polysaccharide; carrier protein; clinical trials; glycoconjugates; immunity; immunology; infectious disease; synthetic drug carriers; vaccines.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Schematic representation of the interactions of polysaccharide (A), polysaccharide and protein coformulation (B), and glycoconjugate (C) with FDC, B cells, and Tfh cells and the associated immune response. For polysaccharide and polysaccharide and protein coformulation, no IgG response and immune memory are induced because of the absence of T cell help. For glycoconjugate, the loading of peptide or glycopeptide into MHC and the engagement of TCR elicits an IgG response and immune memory.
See this image and copyright information in PMC

References

    1. Astronomo RD, Burton DR. 2010. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9:308–324. doi:10.1038/nrd3012. - DOI - PMC - PubMed
    1. Costantino P, Rappuoli R, Berti F. 2011. The design of semi-synthetic and synthetic glycoconjugate vaccines. Expert Opin Drug Discov 6:1045–1066. doi:10.1517/17460441.2011.609554. - DOI - PubMed
    1. Jones C. 2005. Vaccines based on the cell surface carbohydrates of pathogenic bacteria. An Acad Bras Ciênc 77:293–324. doi:10.1590/S0001-37652005000200009. - DOI - PubMed
    1. Pollard AJ, Perrett KP, Beverley PC. 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9:213–220. doi:10.1038/nri2494. - DOI - PubMed
    1. Prasad AK. (ed). 2019. Carbohydrate-based vaccines: from concept to clinic. ACS Symposium Series 1290, p 1–6. American Chemical Society, Washington, DC.

LinkOut - more resources